AZNAcerta Pharma BVRunning, no new patients
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Lymphoma, Mantle Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 635 (final count)
- Started
- Apr 5, 2017
- Main results expected
- Feb 15, 2027
- Fully finished
- Feb 15, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2
Measured over: Up to 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02972840 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC